Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction.
about
Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?Hypertriglyceridemia and Cardiovascular Diseases: RevisitedPrescription omega-3 fatty acid products: considerations for patients with diabetes mellitusMendelian randomization studies: a review of the approaches used and the quality of reportingAssociation of two common polymorphisms of apolipoprotein A5 gene with metabolic syndrome indicators in a North Iranian population, a cross-sectional study.Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Saturated Fat Consumption and Risk of Coronary Heart Disease and Ischemic Stroke: A Science Update.Discordant Lipid Pattern and Carotid Atherosclerotic Plaque. Importance of Remnant CholesterolMetabolic syndrome and its predictors in an urban population in Kenya: A cross sectional study.The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease.Triglycerides on the rise: should we swap seats on the seesaw?Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice.Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State.Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease: a case-control and meta-analysis study.Genomic and transcriptomic predictors of triglyceride response to regular exerciseHypercoagulation and elevation of blood triglycerides are characteristics of Kawasaki diseaseBezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trialEffect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placeboSurprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.The Treatment of Disorders of Lipid MetabolismRemnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies.Dyslipidemia in obesity: mechanisms and potential targetsTriglyceride and cardiovascular risk: A critical appraisal.Discrepant association of serum C-3 epimer of 25-hydroxyvitamin D versus non-epimeric 25-hydroxyvitamin D with serum lipid levels.Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetesPredictive value of non-fasting remnant cholesterol for short-term outcome of diabetics with new-onset stable coronary artery disease.Genetic insights into cardiometabolic risk factorsNovel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids.Demystifying the management of hypertriglyceridaemia.Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.Effects of dyslipidaemia on monocyte production and function in cardiovascular disease.Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease.Update on APOA5 Genetics: Toward a Better Understanding of Its Physiological Impact.Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype.Very-low and low-density lipoproteins induce neutral lipid accumulation and impair migration in monocyte subsets.Validation of a Newly Developed Equation for Estimating Serum Apolipoprotein B: Associations with Cardiovascular Disease Surrogate Markers in Koreans.Hypertriglyceridemia and atherosclerosis.Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals.
P2860
Q26746279-CB33A81D-D071-4DC2-9300-131B775CB3EEQ26750954-DCA0D212-5150-4187-8249-796319A3E8BBQ26752919-5A119D57-33E4-4F00-863E-814E6DDE782FQ26999349-5432526D-FE49-47FD-A6EE-2DE81041223FQ33649101-FE937485-7718-4FFA-952F-B54144A816C3Q33776194-D73F8CE3-81A1-4D99-A3A5-6C1AE7EF3A89Q33810706-8EE833FA-5BA8-4A82-BAD6-10CB582ED3D4Q33848771-0BF5AF6B-81BA-43A5-AC44-3FBAC025C300Q33869151-33055895-6C2A-448B-8287-F7B157423CB0Q34359967-92A8F33B-84EF-47FC-AB53-BE882F3C65F9Q34551430-0A9E3B8C-1D9C-45FD-AA12-582D84C7467FQ35692664-90B14265-70B4-451E-82BC-95A527C3010DQ35753514-5687059F-45D6-4873-A396-70ED3E72CB67Q35995921-43287C2D-95B5-402D-9410-EAD881D362A4Q36011783-0565A4E7-1659-48ED-A49C-D992870602C5Q36073931-9002BD47-C108-4831-BC62-A2A4AE0E2853Q36354476-5E861C3D-4675-4C4D-8AF6-22EF00E3B5E5Q36416679-915BE2D2-3088-4C7B-91DF-BE3593FBFFD6Q36489752-DBE1AC2A-F375-402A-B02B-5C511C5F5F05Q36577724-7591E9D7-15E4-40A8-8D3E-24010D02E043Q36602779-86A7D4BF-99D0-438A-AD7E-376232606978Q36882866-C57C0C80-9A03-4995-AC4E-7002EC23BCCAQ36956660-3675ED15-8325-4BA5-AE04-E47F7FCDF80CQ36994072-AD9BA194-B666-44CE-BD0A-C6A3F7F01853Q37015549-E64254EB-9818-49C7-BBA3-F1D929B07F4BQ37260464-1A3FC264-5CF2-4988-9B04-FBD70DB9BE85Q37278695-6BD39F52-75EF-4937-AEF8-206017436084Q37586680-87311662-B669-4C2B-9C05-7067A53236AAQ37654526-B0202221-22EA-44BA-80DD-CCCC493A485AQ37683866-48014CF9-D72B-4EA7-9A75-C4B315A8F980Q38141575-736CF227-39EA-442E-B04B-00A50117984DQ38546242-55A90C0B-2F8A-4B7B-B4A5-876B04AB0302Q38903993-5B11FFCC-63CF-4D60-8110-76AC67435801Q38924697-406B35A7-866A-43F7-882E-7A32088A9F35Q39303512-F5576AA4-3E94-4623-9879-80E6C39C304CQ39320394-39E670F1-02DC-4D69-AEF6-265B5D909AA6Q40048017-EC9AE680-8BA6-4161-9732-99A453E854C5Q41352387-52981C4D-F3FE-4FC1-AFA0-B34B40ABBA3FQ47180199-2A46F952-90C6-446B-BBB3-25039A1EFE00Q47307583-0E599A7E-178D-40C4-B123-529133C1D03A
P2860
Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Genetically elevated non-fasti ...... ors for myocardial infarction.
@ast
Genetically elevated non-fasti ...... ors for myocardial infarction.
@en
Genetically elevated non-fasti ...... ors for myocardial infarction.
@nl
type
label
Genetically elevated non-fasti ...... ors for myocardial infarction.
@ast
Genetically elevated non-fasti ...... ors for myocardial infarction.
@en
Genetically elevated non-fasti ...... ors for myocardial infarction.
@nl
prefLabel
Genetically elevated non-fasti ...... ors for myocardial infarction.
@ast
Genetically elevated non-fasti ...... ors for myocardial infarction.
@en
Genetically elevated non-fasti ...... ors for myocardial infarction.
@nl
P2093
P2860
P356
P1476
Genetically elevated non-fasti ...... ors for myocardial infarction.
@en
P2093
Anders Berg Jørgensen
Anders Sode West
Peer Grande
Ruth Frikke-Schmidt
P2860
P304
P356
10.1093/EURHEARTJ/EHS431
P577
2012-12-17T00:00:00Z